The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
The multicellular tumor spheroid model for high-throughput cancer drug discovery
Abstract
INTRODUCTION: For the past 30 years 2D-cell-based assay models have dominated preclinical cancer drug discovery efforts. 2D-cell-based models fail to predict in vivo efficacy, contributing to a lower success rate and higher cost required to translate an investigational new drug to clinical approval. Technological advances in 3D-cell culture models bridge the gap between 2D and in vivo models to improve upon the current success rates of cancer drug discovery. AREAS COVERED: This review focuses on the multicellular tumor spheroid (MCTS), particularly how this model can be utilized for HTS drug discovery. We discuss the current technologies for uniform culture of MCTS suitable for HTS and detection methods utilized for assay development and drug screening. EXPERT OPINION: Substantial hurdles remain before we reach the ultimate goal of robust HTS of large compound libraries with MCTS models. Specifically, we can group these challenges into three categories: MCTS growth, data collection, and data analysis. The MCTS model should be utilized with fluorescent readouts and high-content imaging with a systems biology approach to model human tumors in vitro. Such models will be more predictive of in vivo efficacy, improving on the current success rates of cancer drug discovery from bench to bedside.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Vermes, I., Haanen, C., Steffens-Nakken, H., & Reutellingsperger, C. (1995) · Journal of Immunological Methods · doi:10.1016/0022-1759(95)00072-i · Cited by 5,410
Systems biology: a brief overview
Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
The third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Bissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970
THE MITOCHONDRIAL DEATH/LIFE REGULATOR IN APOPTOSIS AND NECROSIS
Kroemer, G., Dallaporta, B., & Resche-Rigon, M. (1998) · Annual Review of Physiology · doi:10.1146/annurev.physiol.60.1.619 · Cited by 1,963
Cited by
Spheroid culture as a tool for creating 3D complex tissues
Fennema, E., Rivron, N., Rouwkema, J., van Blitterswijk, C., & de Boer, J. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.12.003 · Cited by 1,054
In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform
Katt, M. E., Placone, A. L., Wong, A. D., Xu, Z. S., & Searson, P. C. (2016) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2016.00012 · Cited by 754
“introduction Spheroids are aggregates of cells grown in suspension or embedded in a 3D matrix using 3D culture methods (Figure 2) (Mueller-Klieser, 1987; Gottfried et al., 2006; Hirschhaeuser et al., 2010; LaBarbera et al., 2012; Fennema et al., 2013).”
BackgroundMethodNunes, A. S., Barros, A. S., Costa, E. C., Moreira, A. F., & Correia, I. J. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.26845 · Cited by 721
3D Cell Culture Systems: Tumor Application, Advantages, and Disadvantages
Habanjar, O., Diab-Assaf, M., Caldefie-Chezet, F., & Delort, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212200 · Cited by 547
Spheroid Culture System Methods and Applications for Mesenchymal Stem Cells
Ryu, N.-E., Lee, S.-H., & Park, H. (2019) · Cells · doi:10.3390/cells8121620 · Cited by 517
Phenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507
Ahmed, N., & Stenvers, K. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00256 · Cited by 482
Three-dimensional in vitro tumor models for cancer research and drug evaluation
Xu, X., Farach-Carson, M. C., & Jia, X. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.07.009 · Cited by 461
Organ-on-a-chip platforms: a convergence of advanced materials, cells, and microscale technologies
Ahadian, S., Civitarese, R., Bannerman, D., Mohammadi, M. H., Lu, R., Wang, E., Davenport‐Huyer, L., Lai, B., Zhang, B., Zhao, Y., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700506 · Cited by 315
Moshksayan, K., Kashaninejad, N., Warkiani, M. E., Lock, J. G., Moghadas, H., Firoozabadi, B., Saidi, M. S., & Nguyen, N.-T. (2018) · Sensors and Actuators B: Chemical · doi:10.1016/j.snb.2018.01.223 · Cited by 267
Mierke, C. T. (2019) · Reports on Progress in Physics · doi:10.1088/1361-6633/ab1628 · Cited by 262
Design of spherically structured 3D in vitro tumor models -Advances and prospects
Ferreira, L. P., Gaspar, V. M., & Mano, J. F. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.05.034 · Cited by 249
“These models provide a platform that can be easily assembled and facilitates high-throughput studies [195], in comparison with more complex scaffold or microfluidic-based models.”
BackgroundBreast cancer models: Engineering the tumor microenvironment
Bahcecioglu, G., Basara, G., Ellis, B. W., Ren, X., & Zorlutuna, P. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.02.006 · Cited by 213
Drug discovery through stem cell-based organoid models
Ranga, A., Gjorevski, N., & Lutolf, M. P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.02.006 · Cited by 195
“Multicellular cancer tumor spheroids (MCTS) represent a wellestablished in vitro model for avascular tumor growth and this model has become a classic reference for 3D studies [5,12].”
Kuen, J., Darowski, D., Kluge, T., & Majety, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182039 · Cited by 192
Huang, B.-W., & Gao, J.-Q. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.005 · Cited by 174
Optimization of liquid overlay technique to formulate heterogenic 3D co-cultures models
Costa, E. C., Gaspar, V. M., Coutinho, P., & Correia, I. J. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25210 · Cited by 156
A review of microfluidic approaches for investigating cancer extravasation during metastasis
Ma, Y.-H. V., Middleton, K., You, L., & Sun, Y. (2018) · Microsystems & Nanoengineering · doi:10.1038/micronano.2017.104 · Cited by 154
Linking hypoxia, DNA damage and proliferation in multicellular tumor spheroids
Riffle, S., Pandey, R. N., Albert, M., & Hegde, R. S. (2017) · BMC Cancer · doi:10.1186/s12885-017-3319-0 · Cited by 142
Yeon, S.-E., No, D. Y., Lee, S.-H., Nam, S. W., Oh, I.-H., Lee, J., & Kuh, H.-J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073345 · Cited by 110
“Recently, microtechnology using biocompatible polymers, such as polyethylene glycol (PEG) and polydimethylsiloxane (PDMS), have created an opportunity to create micro-multiwell plates that are surrounded by adhesion-resistant surfaces [8,18].”
BackgroundSynthetic tumor networks for screening drug delivery systems
Prabhakarpandian, B., Shen, M.-C., Nichols, J. B., Garson, C. J., Mills, I. R., Matar, M. M., Fewell, J. G., & Pant, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.018 · Cited by 57
Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22475 · Cited by 43
“A number of recent studies provided evidence that the generation of 3D cancer models can be automatized and used for high-throughput phenotypebased drug discovery [17, 18, 26, 27, 45, 116, 130, 131].”
Background3D fluid-dynamic ovarian cancer model resembling systemic drug administration for efficacy assay
Marrella, A. (2020) · ALTEX · doi:10.14573/altex.2003131 · Cited by 36
3D Tumor Spheroid Models for In Vitro Therapeutic Screening of Nanoparticles
Daunys, S., Janonienė, A., Januškevičienė, I., Paškevičiūtė, M., & Petrikaitė, V. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_11 · Cited by 32
Solomon, M. A., Lemera, J., & D’Souza, G. G. M. (2016) · Journal of Liposome Research · doi:10.3109/08982104.2015.1105820 · Cited by 30
“The major limitation of spheroid-based systems is that currently they have not been adapted to highthroughput testing on a similar scale as monolayers have been (LaBarbera et al., 2012; Mehta et al., 2012).”
Background
Metadata
- Authors
- LaBarbera, D. V., Reid, B. G., & Yoo, B. H.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2012-07-12
- Volume
- 7
- Issue
- 9
- Pages
- 819-830
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2148512402
- Cited by
- 255
- References
- 98
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.